Sunitinib

證據等級: L5 預測適應症: 10

目錄

  1. Sunitinib
  2. Sunitinib: From Renal Cell Carcinoma to Liposarcoma
    1. One-Sentence Summary
    2. Quick Overview
    3. Why is This Prediction Reasonable?
    4. Clinical Trial Evidence
    5. Literature Evidence
    6. New Zealand Market Information
    7. Cytotoxicity
    8. Safety Considerations
    9. Conclusion and Next Steps
    10. Disclaimer

## 藥師評估報告

Sunitinib: From Renal Cell Carcinoma to Liposarcoma

One-Sentence Summary

Sunitinib is a multitargeted tyrosine kinase inhibitor whose established, mechanistically-founded indication is renal cell carcinoma (confirmed within this evidence pack via its role as a direct comparator/standard-of-care arm across the RCC trial set). The TxGNN model predicts it may also be effective for Liposarcoma, with 3 clinical trials and 9 publications currently supporting this direction.


Quick Overview

Item Content
Original Indication Renal Cell Carcinoma (inferred from evidence-pack rationale for the RCC prediction, which states this reflects sunitinib's originally approved MOA, not a repurposing hypothesis; formal TFDA label text is a blocking data gap, DG001)
Predicted New Indication Liposarcoma
TxGNN Prediction Score 99.87%
Evidence Level L2
New Zealand Market Status ✗ Not Marketed
Number of Authorizations 0
Recommended Decision Research Question

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002 — DrugBank MOA lookup pending). Based on the information available in this evidence pack, sunitinib is a multitargeted receptor tyrosine kinase inhibitor (VEGFR1-3, PDGFR-α/β, KIT, RET), and its efficacy in renal cell carcinoma — which is highly dependent on VEGF-driven tumor angiogenesis — is well established; this is corroborated by dozens of RCC trials in the evidence pack where sunitinib serves as the active comparator/standard-of-care arm (see Rank 9: "renal carcinoma").

Liposarcoma, particularly the dedifferentiated and myxoid/round-cell subtypes, frequently shows activated PDGFR-β signaling and angiogenesis dependence — mechanistically within reach of sunitinib's anti-VEGFR/PDGFR activity. Two Phase 2 sarcoma trials in the evidence pack (NCT00400569, n=48; NCT00474994, n=53) directly tested sunitinib in metastatic/unresectable soft-tissue sarcoma populations that included liposarcoma, and case-level literature reports durable clinical benefit in heavily pretreated metastatic liposarcoma. However, response rates vary substantially by histological subtype, and no liposarcoma-specific randomized trial has been completed, which is why the evidence level remains L2 with a "Research Question" recommendation rather than a stronger decision.


Clinical Trial Evidence

Trial Number Phase Status Enrollment Key Findings
NCT00400569 Phase 2 Completed 48 Open-label Phase II trial of sunitinib malate in adult patients with metastatic/unresectable soft-tissue sarcoma, including liposarcoma, leiomyosarcoma, fibrosarcoma, and MFH
NCT00474994 Phase 2 Completed 53 Multicenter continuous-dosing sunitinib trial in non-GIST sarcomas, covering liposarcoma subtypes
NCT02048371 Phase 2 Completed 131 SARC024: primarily evaluated regorafenib (not sunitinib) across sarcoma subtypes; only indirectly relevant as precedent for TKI activity in soft-tissue sarcoma

Literature Evidence

PMID Year Type Journal Key Findings
21154746 2011 Phase 2 (non-RCT) International Journal of Cancer Phase II study of sunitinib malate in relapsed/refractory soft-tissue sarcoma, focused on leiomyosarcoma, liposarcoma, and MFH
23482782 2013 Case report Anticancer Research Long-lasting clinical benefit of sunitinib in a heavily pretreated metastatic liposarcoma case
38254762 2024 Review/Genomic Cancers Genetic, epigenetic, and transcriptomic alterations in liposarcoma relevant to target-therapy selection
22987955 2012 Review Annals of Oncology Histology- and non-histology-driven therapy for soft-tissue sarcomas, including subtype-specific drug sensitivities
24555529 2014 Review Expert Review of Anticancer Therapy Emerging therapies for adult soft-tissue sarcoma
24712007 2014 Review Magyar Onkologia Medical treatment of soft-tissue sarcomas based on histological subtype
28423517 2017 Genomic/Translational Oncotarget Next-generation sequencing of extraskeletal myxoid chondrosarcoma, evaluating predictors of sunitinib benefit
25884155 2015 Trial protocol BMC Cancer REGOSARC trial protocol (regorafenib in advanced soft-tissue sarcoma); background context on TKI activity in sarcoma
38717131 2024 Case series American Journal of Surgical Pathology Clinicopathologic analysis of myxoid inflammatory myofibroblastic sarcoma (25 cases); background sarcoma-classification context, not sunitinib-specific

New Zealand Market Information

Sunitinib currently holds no product authorizations in New Zealand (market status: Not Marketed, 0 licenses on record).


Cytotoxicity

Item Content
Cytotoxicity Classification Targeted therapy (multitargeted receptor tyrosine kinase inhibitor)
Myelosuppression Risk Please refer to the package insert warnings and precautions
Emetogenicity Classification Please refer to the package insert warnings and precautions
Monitoring Items Please refer to the package insert warnings and precautions
Handling Protection Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.


Conclusion and Next Steps

Decision: Research Question

Rationale: Two Phase 2 trials and case-level literature show mechanistic plausibility and some clinical benefit for sunitinib in liposarcoma, but no liposarcoma-specific randomized trial exists, and response is subtype-dependent — evidence supports a defined research question rather than a Go/Hold decision at this time.

To proceed, the following is needed:

  • TFDA/regulatory package insert data (blocking gap, DG001) to complete the S1 safety pre-screen
  • Formal DrugBank mechanism-of-action data (DG002) to strengthen the mechanistic-link analysis
  • A liposarcoma-subtype-stratified prospective or retrospective study to clarify which histological subtypes (e.g., dedifferentiated, myxoid/round-cell) respond
  • Drug interaction and myelosuppression/emetogenicity data specific to New Zealand labeling, since the product is not currently marketed there

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



Back to top

Copyright © 2026 藥提醒科技有限公司 (yao.care). This report is for research purposes only and does not constitute medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.